Work

P.323 Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients at imminent risk for suicide: aspire-1 study

Year: 2019

Type: article

Study design: Observational Study

Source: European Neuropsychopharmacology

DOI: 10.1016/j.euroneuro.2019.09.343

Authors: D.J. Fu, C.M. Canuso, D.F. Ionescu, X. Li, R. Lane, P. Lim, D. Hough, W. Drevets, H. Manji

Language: English

Topic: Treatment of Major Depression

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4249867908

FWCI: 0.262

Cites: 1

Cited by: 2

Related to: 10